Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Transl Lung Cancer Res
2014 Oct 01;35:291-300. doi: 10.3978/j.issn.2218-6751.2014.10.01.
Show Gene links
Show Anatomy links
Molecular testing in lung cancer in the era of precision medicine.
Popper HH
,
Ryska A
,
Tímár J
,
Olszewski W
.
???displayArticle.abstract???
The clinical expectations how pathologists should submit lung cancer diagnosis have changed dramatically. Until mid 90-ties a clear separation between small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) was mostly sufficient. With the invention of antiangiogenic treatment a differentiation between squamous and non-squamous NSCLC was requested. When epidermal growth factor receptor (EGFR) mutation was detected in patients with pulmonary adenocarcinomas and subsequent specific treatment with tyrosine kinase inhibitors (TKIs) was invented, sub-classification of NSCLC and molecular analysis of the tumor tissue for mutations was asked for. Pathologists no longer submit just a diagnosis, but instead are involved in a multidisciplinary team for lung cancer patient management. After EGFR several other driver genes such as echinoderm microtubule associated protein like 4-AL-Kinase 1 (EML4-ALK1), c-ros oncogene 1, receptor tyrosine kinase (ROS1), discoidin domain receptor tyrosine kinase 2 (DDR2), fibroblast growth factor receptor 1 (FGFR1) were discovered, and more to come. Due to new developments in bronchology (EUS, EBUS) the amount of tissue submitted for diagnosis and molecular analysis is decreasing, however, the genes to be analyzed are increasing. Many of these driver gene aberrations are inversions or translocations and thus require FISH analysis. Each of these analyses requires a certain amount of tumor cells or one to two tissue sections from an already limited amount of tissues or cells. In this respect new genetic test systems have been introduced such as next generation sequencing, which enables not only to detect multiple mutations in different genes, but also amplifications and fusion genes. As soon as these methods have been validated for routine molecular analysis this will enable the analysis of multiple genetic changes simultaneously. In this review we will focus on genetic aberrations in NSCLC, resistance to new target therapies, and also to methodological requirements for a meaningful evaluation of lung cancer tissue and cells.
Abdollahi,
Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
2003, Pubmed
Abdollahi,
Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
2003,
Pubmed
Adjei,
Pharmacology and mechanism of action of pemetrexed.
2004,
Pubmed
An,
Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.
2012,
Pubmed
Antoniu,
Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis.
2010,
Pubmed
Arai,
Mouse model for ROS1-rearranged lung cancer.
2013,
Pubmed
Arinaga,
Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma.
2003,
Pubmed
Awad,
Acquired resistance to crizotinib from a mutation in CD74-ROS1.
2013,
Pubmed
Bean,
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
2007,
Pubmed
Bergethon,
ROS1 rearrangements define a unique molecular class of lung cancers.
2012,
Pubmed
Besse,
A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer.
2014,
Pubmed
Boreddy,
Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-α/VEGF/Rho-GTPases: pivotal role of STAT-3.
2011,
Pubmed
Cai,
Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).
2008,
Pubmed
Chin,
Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.
2012,
Pubmed
Costa,
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
2008,
Pubmed
Das,
A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma.
2005,
Pubmed
Decaussin,
Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival.
1999,
Pubmed
Drilon,
Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy.
2012,
Pubmed
Dutt,
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.
2011,
Pubmed
Friboulet,
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
2014,
Pubmed
Gazdar,
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
2009,
Pubmed
Giovannetti,
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
2008,
Pubmed
Goyal,
Endorepellin affects angiogenesis by antagonizing diverse vascular endothelial growth factor receptor 2 (VEGFR2)-evoked signaling pathways: transcriptional repression of hypoxia-inducible factor 1α and VEGFA and concurrent inhibition of nuclear factor of activated T cell 1 (NFAT1) activation.
2012,
Pubmed
Grant,
Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival.
2002,
Pubmed
Hellmann,
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab.
2013,
Pubmed
Ikeda,
Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer.
2008,
Pubmed
Isobe,
Current management of advanced non-small cell lung cancer: targeted therapy.
2005,
Pubmed
Ju,
A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.
2012,
Pubmed
Jänne,
ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma.
2012,
Pubmed
Kajita,
The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer.
2001,
Pubmed
Katayama,
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
2011,
Pubmed
,
Echinobase
Katayama,
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
2012,
Pubmed
Kim,
Regulation of epidermal growth factor receptor internalization by G protein-coupled receptors.
2003,
Pubmed
Kojima,
Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma.
2005,
Pubmed
Komiya,
Response to crizotinib in ROS1-rearranged non-small-cell lung cancer.
2012,
Pubmed
Koukourakis,
Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma.
2005,
Pubmed
Kumar,
Impaired microRNA processing enhances cellular transformation and tumorigenesis.
2007,
Pubmed
Langer,
The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
2005,
Pubmed
Li,
Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis.
2002,
Pubmed
Lin,
Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor.
2005,
Pubmed
Lynch,
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
2004,
Pubmed
Mae,
Gene transfer of the vascular endothelial growth factor receptor flt-1 suppresses pulmonary metastasis associated with lung growth.
2005,
Pubmed
Mak,
The tuberous sclerosis complex genes in tumor development.
2004,
Pubmed
Morelli,
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.
2006,
Pubmed
Nakao,
Long-term outcomes of 50 cases of limited-resection trial for pulmonary ground-glass opacity nodules.
2012,
Pubmed
Niki,
Expression of vascular endothelial growth factor receptor 3 in blood and lymphatic vessels of lung adenocarcinoma.
2001,
Pubmed
Nomura,
Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers.
2007,
Pubmed
Norkowski,
Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology.
2013,
Pubmed
Olaussen,
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
2006,
Pubmed
Oxnard,
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.
2011,
Pubmed
Paez,
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
2004,
Pubmed
Palmer,
Anaplastic lymphoma kinase: signalling in development and disease.
2009,
Pubmed
,
Echinobase
Pirker,
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
2012,
Pubmed
Rajadurai,
Met receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodia.
2012,
Pubmed
Ramalingam,
Second-generation ALK inhibitors: filling the non "MET" gap.
2014,
Pubmed
Rho,
The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
2009,
Pubmed
Rimkunas,
Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
2012,
Pubmed
Rossi,
Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology.
2014,
Pubmed
Sarvi,
CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist.
2014,
Pubmed
Scagliotti,
ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
2012,
Pubmed
Sharma,
Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.
2014,
Pubmed
Shien,
Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.
2013,
Pubmed
Sordella,
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
2004,
Pubmed
Spigel,
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
2013,
Pubmed
Strazisar,
Somatic alterations of the serine/threonine kinase LKB1 gene in squamous cell (SCC) and large cell (LCC) lung carcinoma.
2009,
Pubmed
Suda,
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.
2010,
Pubmed
Suehara,
Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
2012,
Pubmed
Sun,
P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: clues from free energy landscape.
2014,
Pubmed
Takahashi,
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
2012,
Pubmed
Takeuchi,
RET, ROS1 and ALK fusions in lung cancer.
2012,
Pubmed
Tsao,
Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers.
1998,
Pubmed
Wang,
RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
2012,
Pubmed
Watanabe,
Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma.
2013,
Pubmed
Weiss,
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.
2010,
Pubmed
Whiteman,
Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.
2014,
Pubmed
Wong,
A novel KIF5B-ALK variant in nonsmall cell lung cancer.
2011,
Pubmed
,
Echinobase
Xie,
Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.
2012,
Pubmed
Yano,
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.
2008,
Pubmed
Yasuda,
Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
2012,
Pubmed
Yu,
Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer.
2013,
Pubmed
Yu,
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
2013,
Pubmed
Zhang,
microRNAs as oncogenes and tumor suppressors.
2007,
Pubmed
Zhang,
Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.
2011,
Pubmed
Zinner,
Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.
2010,
Pubmed
